BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23465272)

  • 1. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of epidermal growth factor receptor mutation specific antibodies in lung adenocarcinoma: evaluation of sensitivity, specificity and relationship to histologic subtypes].
    Lai YM; Feng Q; Sun Y; Wang P; Shi YF; Zhao M; Wu Q; Li XH
    Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):606-11. PubMed ID: 27646888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
    Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
    Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunohistochemistry using epidermal growth factor receptor mutation-specific antibodies of delE746-A750 and L858R in lung adenocarcinomas].
    Fan XS; Liu B; Yu B; Shi SS; Wang X; Zhang J; Wang JD; Lu ZF; Ma HH; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):173-7. PubMed ID: 23769436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
    Wu SG; Chang YL; Lin JW; Wu CT; Chen HY; Tsai MF; Lee YC; Yu CJ; Shih JY
    PLoS One; 2011; 6(8):e23303. PubMed ID: 21858063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
    Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
    J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
    Wang X; Wang G; Hao Y; Xu Y; Zhang L
    Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
    Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
    J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
    Kozu Y; Tsuta K; Kohno T; Sekine I; Yoshida A; Watanabe S; Tamura T; Yokota J; Suzuki K; Asamura H; Furuta K; Tsuda H
    Lung Cancer; 2011 Jul; 73(1):45-50. PubMed ID: 21129809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.
    Ping W; Xia C; Fu S; Cai Y; Deng Y; Sun W; Dong C; Fu X
    Tumour Biol; 2015 Feb; 36(2):693-700. PubMed ID: 25286755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal Growth Factor Receptor Gene Mutation Detection in Histology and Cytology Specimens of Primary Lung Adenocarcinoma: Immunohistochemistry Versus the Molecular Method.
    Abdul Hamid NS; Mat Zin AA
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1935-1942. PubMed ID: 34181354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies.
    Xiong Y; Bai Y; Leong N; Laughlin TS; Rothberg PG; Xu H; Nong L; Zhao J; Dong Y; Li T
    Diagn Pathol; 2013 Feb; 8():27. PubMed ID: 23419122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
    Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R
    Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between EGFR Mutations and Pathological Classification and 
Specimen of Lung Adenocarcinoma].
    Kang L; Zheng J; Zhu X
    Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):382-388. PubMed ID: 28641695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
    Hasanovic A; Ang D; Moreira AL; Zakowski MF
    Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
    Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
    BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.